H. Wallick
- Molecular Medicine top 1%
- Antibiotic Resistance in Bacteria 4
- Pharmacology top 2%
- Antibiotics Pharmacokinetics and Efficacy 9
- Microbial Natural Products and Biosynthesis 4
- Small Animals top 2%
- Microbiology top 10%
- Insect Science top 5%
-
- Synthesis and Biological Activity 3
-
- Phenothiazines and Benzothiazines Synthesis and Activities 3
-
- Pharmaceutical and Antibiotic Environmental Impacts 2
-
- Blood disorders and treatments 2
-
- Antimicrobial Resistance in Staphylococcus 2
H. Wallick
16 papers receiving 1.5k citations
Hit Papers
Peers
Comparison fields: 5 of 111
- Molecular Medicine 315
- Pharmacology 553
- Small Animals 172
- Microbiology 14
- Insect Science 178
Countries citing papers authored by H. Wallick
This map shows the geographic impact of H. Wallick's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H. Wallick with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H. Wallick more than expected).
Fields of papers citing papers by H. Wallick
This network shows the impact of papers produced by H. Wallick. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H. Wallick. The network helps show where H. Wallick may publish in the future.
Co-authorship network
The 25 scholars most cited alongside H. Wallick, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Discovery and antimicrobial properties of cathomycin, a new antibiotic produced by Streptomyces spheroides n. sp. | 2002 | 8 |
| 2 | 1979 | 36 | |
| 3 | 1979 | 4 | |
| 4 | Avermectins, New Family of Potent Anthelmintic Agents: Producing Organism and Fermentationbreakdown → | 1979 | 728 |
| 5 | 1978 | 32 | |
| 6 | 1977 | 47 | |
| 7 | 1974 | 86 | |
| 8 | 1974 | 34 | |
| 9 | 1973 | 51 | |
| 10 | Clinical pharmacology of pivampicillin. | 1970 | 38 |
| 11 | Phosphonomycin, a New Antibiotic Produced by Strains of Streptomycesbreakdown → | 1969 | 473 |
| 12 | Pharmacodynamics of phosphonomycin after oral administration in man. | 1969 | 7 |
| 13 | Pharmacodynamics of phosphonomycin after intravenous administration in man. | 1969 | 5 |
| 14 | Antibiotic MSD-819. I. Microbial production and biological characteristics. | 1968 | 2 |
| 15 | 1960 | 58 | |
| 16 | Discovery, development, and antimicrobial properties of D-4-amino-3-isoxazolidone (oxamycin), a new antibiotic produced by Streptomyces garyphalus n. sp. | 1955 | 30 |
About H. Wallick
H. Wallick is a scholar working on Pharmacology, Molecular Medicine, Toxicology, Cancer Research and Pollution, having authored 16 papers that have together received 1.6k indexed citations. Recurring topics across this work include Antibiotics Pharmacokinetics and Efficacy (9 papers), Microbial Natural Products and Biosynthesis (4 papers), Antibiotic Resistance in Bacteria (4 papers), Synthesis and Biological Activity (3 papers), Phenothiazines and Benzothiazines Synthesis and Activities (3 papers), Pharmaceutical and Antibiotic Environmental Impacts (2 papers), Blood disorders and treatments (2 papers) and Antimicrobial Resistance in Staphylococcus (2 papers). The work is most often cited by research in Molecular Medicine (315 citations), Pharmacology (553 citations), Small Animals (172 citations), Microbiology (14 citations) and Insect Science (178 citations). H. Wallick has collaborated with scholars based in United States, Belgium and Japan. Frequent co-authors include E. O. Stapley, David Hendlin, Jerome Birnbaum, H. B. Woodruff, A. Kathrine Miller, Satoshi Ōmura, Irving Putter, Robert Hartman, Richard W. Burg and Brinton M. Miller. Their work appears in journals such as Antimicrobial Agents and Chemotherapy, Clinical Infectious Diseases, Infection, Science and Clinical Pharmacology & Therapeutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.